AEterna Zentaris Inc. Stock
AEterna Zentaris Inc. Stock
Pros and Cons of AEterna Zentaris Inc. in the next few years
Pros
Cons
Performance of AEterna Zentaris Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
AEterna Zentaris Inc. | - | - | - | - | - | - | - |
Satellos Bioscience Inc. | 4.760% | 0.654% | -2.532% | -15.385% | 11.594% | -75.938% | - |
Burcon Nutrascience Corp. | -4.360% | 6.534% | 12.952% | 13.982% | 40.977% | -93.883% | -61.260% |
Sirona Biochem Corp. | 2.470% | -1.149% | -1.149% | -53.664% | -33.846% | -77.487% | -83.137% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon examining the financial health of AEterna Zentaris, a player in the biotechnology and medical research industry, the immediate observation is that this company paints a picture of considerable financial challenges. With a modest market capitalization of approximately $8.61 million and an EBITDA which stands at a negative $15.70 million, one can infer that the company’s earnings before interest, taxes, depreciation, and amortization are not sufficient to cover these expenses, implying operational difficulties.
With a deep dive into the details, let us first elucidate the strengths or potential upsides in AEterna Zentaris' financial situation:
Conversely, a comprehensive analysis reveals a more extensive list of concerns:
Comments